The highly attenuated Orf virus strain D1701 was used to generate a recombinant virus (D1701-VrVp40) expressing nucleoprotein p40 of Borna disease virus (Henkel et al., 2005).
f. Immunization Route
Intramuscular injection (i.m.)
g.
Rat Response
Vaccination Protocol:
The rats were immunized at an age of 4 to 5 weeks in 2-week intervals by intramuscular application of D1701-VrVp40 (Henkel et al., 2005).
Vaccine Immune Response Type:
VO_0000287
Challenge Protocol:
2 weeks after the last immunization 5 ×10^3 to 10 ×10^3 FFU of BDV were used for intracerebral challenge infection (Henkel et al., 2005).
Efficacy:
Rats immunized with D1701-VrVp40 exhibited protection against Borna Disease, and virus clearance from the infected brain was demonstrated in immunized animals. Even 4 and 8 months after the last immunization, all immunized animals were still protected against the disease (Henkel et al., 2005).
IV. References
1. Hashimoto et al., 2003: Hashimoto Y, Chen HS, Cunningham C, Malik TH, Lai PK. Two major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunization. Journal of virology. 2003; 77(10); 6076-6081. [PubMed: 12719601].
2. Henkel et al., 2005: Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology. 2005; 79(1); 314-325. [PubMed: 15596826].
